Research ArticleExpert Review
Open Access

Management of Calcinosis Cutis in Rheumatic Diseases

Hadiya Elahmar, Brian M. Feldman and Sindhu R. Johnson
The Journal of Rheumatology September 2022, 49 (9) 980-989; DOI: https://doi.org/10.3899/jrheum.211393

REFERENCES

  1. 1.↵
    1. Walsh JS,
    2. Fairley JA.
    Calcifying disorders of the skin. J Am Acad Dermatol 1995;33:693–706.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Gutierrez A Jr,
    2. Wetter DA.
    Calcinosis cutis in autoimmune connective tissue diseases. Dermatol Ther 2012;25:195–206.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Lin SY.
    Biochemical and molecular aspects of spectral diagnosis in calcinosis cutis. Expert Rev Mol Med 2014;16:e6.
    OpenUrl
  4. 4.↵
    1. Nielsen AO,
    2. Johnson E,
    3. Hentzer B,
    4. Kobayasi T.
    Dermatomyositis with universal calcinosis. A histopathological and electron optic study. J Cutan Pathol 1979;6:486–91.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Boulman N,
    2. Slobodin G,
    3. Rozenbaum M,
    4. Rosner I.
    Calcinosis in rheumatic diseases. Semin Arthritis Rheum 2005;34:805–12.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Le C,
    2. Bedocs PM.
    Calcinosis Cutis. StatPearls. Treasure Island: StatPearls Publishing; 2021.
  7. 7.↵
    1. Cruz-Dominguez MP,
    2. Garcia-Collinot G,
    3. Saavedra MA, et al.
    Clinical, biochemical, and radiological characterization of the calcinosis in a cohort of Mexican patients with systemic sclerosis. Clin Rheumatol 2017;36:111–7.
    OpenUrl
  8. 8.↵
    1. Vayssairat M HD,
    2. Abdoucheli-Baudot N,
    3. Gaitz JP.
    Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis. Does diltiazem induce its regression? Ann Rheum Dis 1998;57:252–4.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Belloli L,
    2. Ughi N,
    3. Massarotti M,
    4. Marasini B,
    5. Biondi ML,
    6. Brambilla G.
    Role of fetuin-A in systemic sclerosis-associated calcinosis. J Rheumatol 2010;37:2638–9.
    OpenUrlFREE Full Text
  10. 10.↵
    1. Valenzuela A,
    2. Baron M,
    3. Herrick AL, et al.
    Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: a Scleroderma Clinical Trials Consortium study. Semin Arthritis Rheum 2016;46:344–9.
    OpenUrl
  11. 11.↵
    1. Baron M,
    2. Pope J,
    3. Robinson D, et al.
    Calcinosis is associated with digital ischaemia in systemic sclerosis–a longitudinal study. Rheumatology 2016;55:2148–55.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Touart DM,
    2. Sau P.
    Cutaneous deposition diseases. Part II. J Am Acad Dermatol 1998;39:527–44.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Pai S,
    2. Hsu V.
    Are there risk factors for scleroderma-related calcinosis? Mod Rheumatol Int 2018;28:518–22.
    OpenUrl
  14. 14.↵
    1. Bartoli F,
    2. Fiori G,
    3. Braschi F, et al.
    Calcinosis in systemic sclerosis: subsets, distribution and complications. Rheumatology 2016;55:1610–4.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Ferri C,
    2. Valentini G,
    3. Cozzi F, et al; Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc)
    . Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002;81:139–53.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Koutaissoff S,
    2. Vanthuyne M,
    3. Smith V, et al.
    Hand radiological damage in systemic sclerosis: comparison with a control group and clinical and functional correlations. Semin Arthritis Rheum 2011;40:455–60.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Avouac J,
    2. Mogavero G,
    3. Guerini H, et al.
    Predictive factors of hand radiographic lesions in systemic sclerosis: a prospective study. Ann Rheum Dis 2011;70:630–3.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Belotti Masserini A,
    2. Zeni S,
    3. Cossutta R,
    4. Soldi A,
    5. Fantini F.
    [Cost-of-illness in systemic sclerosis: a retrospective study of an Italian cohort of 106 patients]. [Article in Italian] Reumatismo 2003;55:245–55.
    OpenUrlPubMed
  19. 19.
    1. Lopez-Bastida J,
    2. Linertova R,
    3. Oliva-Moreno J,
    4. Posada-de-la-Paz M,
    5. Serrano-Aguilar P.
    Social economic costs and health-related quality of life in patients with systemic sclerosis in Spain. Arthritis Care Res 2014;66:473–80.
    OpenUrl
  20. 20.
    1. Chevreul K,
    2. Brigham KB,
    3. Gandre C,
    4. Mouthon L; BURQOL-RD Research Network
    . The economic burden and health-related quality of life associated with systemic sclerosis in France. Scand J Rheumatol 2015;44:238–46.
    OpenUrl
  21. 21.↵
    1. Johnson SR,
    2. Glaman DD,
    3. Schentag CT,
    4. Lee P.
    Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. J Rheumatol 2006;33:1117–22.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Steen VD,
    2. Ziegler GL,
    3. Rodnan GP,
    4. Medsger TA Jr.
    Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 1984;27:125–31.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Mierau R,
    2. Moinzadeh P,
    3. Riemekasten G, et al.
    Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 2011;13:R172.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Bowyer SL,
    2. Blane CE,
    3. Sullivan DB,
    4. Cassidy JT.
    Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983;103:882–8.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Tansley SL,
    2. Simou S,
    3. Shaddick G, et al.
    Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort. J Autoimmun 2017;84:55–64.
    OpenUrl
  26. 26.↵
    1. Chung MP,
    2. Richardson C,
    3. Kirakossian D, et al; International Myositis Assessment; Clinical Studies Group (IMACS) Calcinosis Scientific Interest Group
    . Calcinosis biomarkers in adult and juvenile dermatomyositis. Autoimmun Rev 2020;19:102533.
    OpenUrl
  27. 27.↵
    1. Davies CA,
    2. Jeziorska M,
    3. Freemont AJ,
    4. Herrick AL.
    The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol 2006;37:190–7.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Park JK,
    2. Fava A,
    3. Carrino J,
    4. Del Grande F,
    5. Rosen A,
    6. Boin F.
    Association of acroosteolysis with enhanced osteoclastogenesis and higher blood levels of vascular endothelial growth factor in systemic sclerosis. Arthritis Rheumatol 2016;68:201–9.
    OpenUrl
  29. 29.↵
    1. Omair MA,
    2. Pagnoux C,
    3. McDonald-Blumer H,
    4. Johnson SR.
    Low bone density in systemic sclerosis. A systematic review. J Rheumatol 2013;40:1881–90.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Lüders S,
    2. Friedrich S,
    3. Ohrndorf S, et al.
    Detection of severe digital vasculopathy in systemic sclerosis by colour Doppler sonography is associated with digital ulcers. Rheumatology 2017;56:1865–73.
    OpenUrl
  31. 31.↵
    1. Davies CA,
    2. Jeziorska M,
    3. Freemont AJ,
    4. Herrick AL.
    Expression of osteonectin and matrix Gla protein in scleroderma patients with and without calcinosis. Rheumatology 2006;45:1349–55.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Wallin R,
    2. Wajih N,
    3. Greenwood GT,
    4. Sane DC.
    Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med Res Rev 2001;21:274–301.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Gauhar R,
    2. Wilkinson J,
    3. Harris J,
    4. Manning J,
    5. Herrick AL.
    Calcinosis preferentially affects the thumb compared to other fingers in patients with systemic sclerosis. Scand J Rheumatol 2016;45:317–20.
    OpenUrl
  34. 34.↵
    1. AlMehmadi BA,
    2. To FZ,
    3. Anderson MA,
    4. Johnson SR.
    Epidemiology and treatment of peripheral neuropathy in systemic sclerosis. J Rheumatol 2021;48:1839–49.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Freire V,
    2. Bazeli R,
    3. Elhai M, et al.
    Hand and wrist involvement in systemic sclerosis: US features. Radiology 2013;269:824–30.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Freire V,
    2. Becce F,
    3. Feydy A, et al.
    MDCT imaging of calcinosis in systemic sclerosis. Clin Radiol 2013;68:302–9.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Chung L,
    2. Valenzuela A,
    3. Fiorentino D, et al; Scleroderma Clinical Trials Consortium Calcinosis Working Group
    . Validation of a novel radiographic scoring system for calcinosis affecting the hands of patients with systemic sclerosis. Arthritis Care Res 2015;67:425–30.
    OpenUrl
  38. 38.↵
    1. Ughi N,
    2. Crotti C,
    3. Ingegnoli F.
    Effectiveness and safety of oxycodone/naloxone in the management of chronic pain in patients with systemic sclerosis with recurrent digital ulcers: two case reports. Clin Interv Aging 2016;11:307–11.
    OpenUrl
  39. 39.↵
    1. Tabarki B,
    2. Ponsot G,
    3. Prieur AM,
    4. Tardieu M.
    Childhood dermatomyositis: clinical course of 36 patients treated with low doses of corticosteroids. Eur J Paediatr Neurol 1998;2:205–11.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Valenzuela A,
    2. Stevens K,
    3. Chung MP, et al.
    Change in calcinosis over 1 year using the scleroderma clinical trials consortium radiologic scoring system for calcinosis of the hands in patients with systemic sclerosis. Semin Arthritis Rheum 2022;53:151980.
    OpenUrl
  41. 41.↵
    1. Farah MJ,
    2. Palmieri GM,
    3. Sebes JI,
    4. Cremer MA,
    5. Massie JD,
    6. Pinals RS.
    The effect of diltiazem on calcinosis in a patient with the CREST syndrome. Arthritis Rheum 1990;33:1287–93.
    OpenUrlPubMed
  42. 42.
    1. Palmieri GM,
    2. Sebes JI,
    3. Aelion JA, et al.
    Treatment of calcinosis with diltiazem. Arthritis Rheum 1995;38:1646–54.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Dolan AL,
    2. Kassimos D,
    3. Gibson T,
    4. Kingsley GH.
    Diltiazem induces remission of calcinosis in scleroderma. Br J Rheumatol 1995; 34:576–8.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Balin SJ,
    2. Wetter DA,
    3. Andersen LK,
    4. Davis MD.
    Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996-2009. Arch Dermatol 2012;148:455–62.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Fredi M,
    2. Bartoli F,
    3. Cavazzana I, et al.
    Calcinosis cutis in poly-dermatomyositis: clinical and therapeutic study. Ann Rheum Dis 2015;74:830–1.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Fuchs D,
    2. Fruchter L,
    3. Fishel B,
    4. Holtzman M,
    5. Yaron M.
    Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis. Clin Rheumatol 1986;5:527–30.
    OpenUrlPubMed
  47. 47.↵
    1. Herrick AL,
    2. Gallas A.
    Systemic sclerosis-related calcinosis. J Scleroderma Relat Disord 2016;1:194–203.
    OpenUrl
  48. 48.↵
    1. Palaniswamy C,
    2. Sekhri A,
    3. Aronow WS,
    4. Kalra A,
    5. Peterson SJ.
    Association of warfarin use with valvular and vascular calcification: a review. Clin Cardiol 2011;34:74–81.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Berger RG,
    2. Featherstone GL,
    3. Raasch RH,
    4. McCartney WH,
    5. Hadler NM.
    Treatment of calcinosis universalis with low-dose warfarin. Am J Med 1987;83:72–6.
    OpenUrlPubMed
  50. 50.↵
    1. Lassoued K,
    2. Saiag P,
    3. Anglade MC,
    4. Roujeau JC,
    5. Touraine RL.
    Failure of warfarin in treatment of calcinosis universalis. Am J Med 1988;84:795–6.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Cukierman T,
    2. Elinav E,
    3. Korem M,
    4. Chajek-Shaul T.
    Low dose warfarin treatment for calcinosis in patients with systemic sclerosis. Ann Rheum Dis 2004;63:1341–3.
    OpenUrlAbstract/FREE Full Text
  52. 52.
    1. Moazedi-Fuerst FC,
    2. Kielhauser SM,
    3. Bodo K,
    4. Graninger WB.
    Dosage of rituximab in systemic sclerosis: 2-year results of five cases. Clin Exp Dermatol 2015;40:211–2.
    OpenUrlCrossRefPubMed
  53. 53.
    1. Narváez J,
    2. Sancho JJA,
    3. Castellvi I, et al.
    Long-term efficacy of rituximab in systemic sclerosis. Arthritis Rheumatol 2014;66 Suppl 10.
  54. 54.↵
    1. Giuggioli D,
    2. Lumetti F,
    3. Colaci M,
    4. Fallahi P,
    5. Antonelli A,
    6. Ferri C.
    Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev 2015;14:1072–8.
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Bader-Meunier B,
    2. Decaluwe H,
    3. Barnerias C, et al; Club Rhumatismes et Inflammation
    . Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol 2011;38:1436–40.
    OpenUrlAbstract/FREE Full Text
  56. 56.↵
    1. Aggarwal R,
    2. Loganathan P,
    3. Koontz D,
    4. Qi Z,
    5. Reed AM,
    6. Oddis CV.
    Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology 2017;56:247–54.
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Daoussis D,
    2. Antonopoulos I,
    3. Liossis SN,
    4. Yiannopoulos G,
    5. Andonopoulos AP.
    Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum 2012;41:822–9.
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. de Paula DR,
    2. Klem FB,
    3. Lorencetti PG,
    4. Muller C,
    5. Azevedo VF.
    Rituximab-induced regression of CREST-related calcinosis. Clin Rheumatol 2013;32:281–3.
    OpenUrlCrossRefPubMed
  59. 59.↵
    1. Poormoghim H,
    2. Andalib E,
    3. Almasi AR,
    4. Hadibigi E.
    Systemic sclerosis and calcinosis cutis: response to rituximab. J Clin Pharm Ther 2016;41:94–6.
    OpenUrl
  60. 60.↵
    1. Dima A,
    2. Balanescu P,
    3. Baicus C.
    Pharmacological treatment in calcinosis cutis associated with connective-tissue diseases. Rom J Intern Med 2014;52:55–67.
    OpenUrl
  61. 61.↵
    1. Tayfur AC,
    2. Topaloglu R,
    3. Gulhan B,
    4. Bilginer Y.
    Bisphosphonates in juvenile dermatomyositis with dystrophic calcinosis. Mod Rheumatol 2015;25:615–20.
    OpenUrl
  62. 62.↵
    1. Marco Puche A,
    2. Calvo Penades I,
    3. Lopez Montesinos B.
    Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol 2010;28:135–40.
    OpenUrlPubMed
  63. 63.↵
    1. Masza Mukamel,
    2. Horev G,
    3. Mimouni M.
    New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr 2001;138:763–6.
    OpenUrlCrossRefPubMed
  64. 64.↵
    1. Rabens SF,
    2. Bethune JE.
    Disodium etidronate therapy for dystrophic cutaneous calcification. Arch Dermatol 1975;111:357–61.
    OpenUrlCrossRefPubMed
  65. 65.↵
    1. Metzger AL,
    2. Singer FR,
    3. Bluestone R,
    4. Pearson CM.
    Failure of disodium etidronate in calcinosis due to dermatomyositis and scleroderma. N Engl J Med 1974;291:1294–6.
    OpenUrlPubMed
  66. 66.↵
    1. Asano Y,
    2. Ihn H,
    3. Asashima N, et al.
    A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. Rheumatology 2005;44:824–6.
    OpenUrlCrossRefPubMed
  67. 67.
    1. Levy Y,
    2. Amital H,
    3. Langevitz P, et al.
    Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum 2004;50:1005–7.
    OpenUrlCrossRefPubMed
  68. 68.↵
    1. Nacci F,
    2. Righi A,
    3. Conforti ML, et al.
    Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis 2007;66:977–9.
    OpenUrlAbstract/FREE Full Text
  69. 69.↵
    1. Kalajian AH,
    2. Perryman JH,
    3. Callen JP.
    Intravenous immunoglobulin therapy for dystrophic calcinosis cutis: unreliable in our hands. Arch Dermatol 2009;145:334.
    OpenUrlCrossRefPubMed
  70. 70.↵
    1. Schanz S,
    2. Ulmer A,
    3. Fierlbeck G.
    Response of dystrophic calcification to intravenous immunoglobulin. Arch Dermatol 2008;144:585–7.
    OpenUrlCrossRefPubMed
  71. 71.↵
    1. Bair B,
    2. Fivenson D.
    A novel treatment for ulcerative calcinosis cutis. J Drugs Dermatol 2011;10:1042–4.
    OpenUrlPubMed
  72. 72.↵
    1. Del Barrio-Diaz P,
    2. Moll-Manzur C,
    3. Alvarez-Veliz S,
    4. Vera-Kellet C.
    Topical sodium metabisulfite for the treatment of calcinosis cutis: a promising new therapy. Br J Dermatol 2016;175:608–11.
    OpenUrl
  73. 73.↵
    1. Baumgartner-Nielsen J,
    2. Olesen AB.
    Treatment of skin calcifications with intra-lesional injection of sodium thiosulphate: a case series. Acta Derm Venereol 2016;96:257–8.
    OpenUrlPubMed
  74. 74.↵
    1. Song P,
    2. Fett NM,
    3. Lin J,
    4. Merola JF,
    5. Costner M,
    6. Vleugels RA.
    Lack of response to intravenous sodium thiosulfate in three cases of extensive connective tissue disease-associated calcinosis cutis. Br J Dermatol 2018;178:1412–5.
    OpenUrlPubMed
  75. 75.↵
    1. Robertson LP,
    2. Marshall RW,
    3. Hickling P.
    Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis 2003;62:267–9.
    OpenUrlAbstract/FREE Full Text
  76. 76.↵
    1. Ebenbichler GR,
    2. Erdogmus CB,
    3. Resch KL, et al.
    Ultrasound therapy for calcific tendinitis of the shoulder. N Engl J Med 1999;340:1533–8.
    OpenUrlCrossRefPubMed
  77. 77.↵
    1. Shetty S,
    2. Moore TL,
    3. Jackson S,
    4. Brettle D,
    5. Herrick AL.
    A pilot study of acetic acid iontophoresis and ultrasound in the treatment of systemic sclerosis-related calcinosis. Rheumatology 2005;44:536–8.
    OpenUrlCrossRefPubMed
  78. 78.↵
    1. Hudson PM,
    2. Jones PE,
    3. Robinson TW,
    4. Dent CE.
    Extensive calcinosis with minimal scleroderma: treatment of ectopic calcification with aluminum hydroxide. Proc R Soc Med 1974;67:1166–8.
    OpenUrlPubMed
  79. 79.↵
    1. Giuggioli D,
    2. Lumetti F,
    3. Spinella A, et al.
    Use of Neem oil and Hypericum perforatum for treatment of calcinosis-related skin ulcers in systemic sclerosis. J Int Med Res 2020;48:300060519882176.
    OpenUrl
  80. 80.↵
    1. Seshadri R,
    2. Feldman BM,
    3. Ilowite N,
    4. Cawkwell G,
    5. Pachman LM.
    The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum 2008;59:989–95.
    OpenUrlCrossRefPubMed
  81. 81.↵
    1. Rider LG,
    2. Miller FW.
    Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 1997;23:619–55.
    OpenUrlCrossRefPubMed
  82. 82.↵
    1. Romicka AM.
    [Use of intravenous megadoses of methylprednisolone for treatment of dermatomyositis in children]. [Article in Polish] Pediatr Pol 1995;70:243–8.
    OpenUrlPubMed
  83. 83.↵
    1. Klein-Gitelman MS,
    2. Waters T,
    3. Pachman LM.
    The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis. Arthritis Care Res 2000;13:360–8.
    OpenUrlCrossRefPubMed
  84. 84.↵
    1. Chung MP,
    2. Valenzuela A,
    3. Li S, et al.
    A pilot study to evaluate the safety and efficacy of treprostinil in the treatment of calcinosis in systemic sclerosis. Rheumatology 2022;61:2441–9.
    OpenUrl
  85. 85.↵
    1. Kahn JS,
    2. Deverapalli SC,
    3. Rosmarin DM.
    JAK-STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis. Int J Dermatol 2018; 57:1007–14.
    OpenUrl
  86. 86.↵
    1. Wendel S,
    2. Venhoff N,
    3. Frye BC, et al.
    Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-kinase inhibitor tofacitinib – a report of two cases. J Autoimmun 2019;100:131–6.
    OpenUrlPubMed
  87. 87.↵
    1. Bogoch ER,
    2. Gross DK.
    Surgery of the hand in patients with systemic sclerosis: outcomes and considerations. J Rheumatol 2005;32:642–8.
    OpenUrlAbstract/FREE Full Text
  88. 88.↵
    1. Fahmy FS,
    2. Evans D,
    3. Devaraj VS.
    Microdrilling of digital calcinosis. Eur J Plast Surg 1998;21:378–80.
    OpenUrl
  89. 89.↵
    1. Bottomley WW,
    2. Goodfield MJ,
    3. Sheehan-Dare RA.
    Digital calcification in systemic sclerosis: effective treatment with good tissue preservation using the carbon dioxide laser. Br J Dermatol 1996;135:302–4.
    OpenUrlCrossRefPubMed
  90. 90.↵
    1. Sultan-Bichat N,
    2. Menard J,
    3. Perceau G,
    4. Staerman F,
    5. Bernard P,
    6. Reguiaï Z.
    Treatment of calcinosis cutis by extracorporeal shock-wave lithotripsy. J Am Acad Dermatol 2012;66:424–9.
    OpenUrlCrossRefPubMed
  91. 91.↵
    1. Blumhardt S,
    2. Frey DP,
    3. Toniolo M,
    4. Alkadhi H,
    5. Held U,
    6. Distler O.
    Safety and efficacy of extracorporeal shock wave therapy (ESWT) in calcinosis cutis associated with systemic sclerosis. Clin Exp Rheumatol 2016;34 Suppl 100:177–80.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

calcinosis cutis
SCLERODERMA
SYSTEMIC SCLEROSIS

Keywords